Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Lilly considering a stake in Turkish drugmaker

September 6, 2011 Manufacturing and Production, Research and Development, Sales and Marketing MN Pharmaceuticals, Turkey, lilly, research and development news

Eli Lilly is reportedly eyeing up a partnership with Turkish drugmaker Mustafa Nevzat Ilac Sanayi (MN Pharmaceuticals) in order to …
News

Health reforms face renewed opposition

September 6, 2011 Sales and Marketing NHS reforms

The government’s health reforms in England are coming under attack once again as the legislation returns to Parliament. After the …
News
Novartis Afinitor

Afinitor expands European licence

September 5, 2011 Sales and Marketing Afinitor, Novartis, Pancreatic cancer

Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
News

NICE rejects three bowel cancer drugs

September 5, 2011 Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer

NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …
News
Boehringer-Lilly's Trajenta

Boehringer-Lilly won’t launch Trajenta in Germany

September 5, 2011 Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts

Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …
News
AstraZeneca's Crestor (rosuvastatin)

Crestor fails head-to-head test against Lipitor

September 2, 2011 Sales and Marketing Crestor, Lipitor

AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …
News

Philippines pricing controls: Pfizer ‘considered taking drugs off the market’

September 2, 2011 Sales and Marketing Drug pricing, Philippines, price cuts

Pfizer considered withdrawing some of its products from the Philippines rather than face planned pricing controls, according to a US …
News

Zonegran study could pave way for paediatric licence

September 2, 2011 Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news

Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …
News

Robert Yates appointed president of Millipore

September 2, 2011 Sales and Marketing appointment, sales and marketing

Merck KGaA has appointed diagnostics expert Robert Yates to the newly-created role of president at Millipore, the company it acquired …
Appointment
Roche's Tarceva (erlotinib)

Tarceva approval for first-line use in EGFR lung cancer

September 1, 2011 Sales and Marketing NSCLC, Roche, Tarceva

Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
News

Shire’s Firazyr gains US approval after initial setback

September 1, 2011 Sales and Marketing FDA, Firazyr, Shire

After three years of waiting Shire’s Firazyr has been approved by the FDA for sudden attacks of swelling. The US …
News

FDA wants more information on Novartis arthritis drug

August 31, 2011 Sales and Marketing FDA, Ilaris, Novarits, canakinumab

The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
News
Boehringer Ingelheim

Pradaxa and Eliquis gain trial boost over warfarin

August 31, 2011 Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban

A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …
News

Nurofen Plus recall expanded

August 31, 2011 Sales and Marketing MHRA, Nurofen, recalls

Last week’s recall of Reckitt Benckiser’s painkiller product Nurofen Plus has been expanded after two additional cases emerged where powerful …
News

FDA approves Pfizer’s lung cancer drug Xalkori

August 30, 2011 Sales and Marketing FDA, Pfizer, Xalkori, crizotinib

Pfizer’s lung cancer drug Xalkori has been approved by the FDA, a month ahead of schedule. Xalkori (crizotinib) is now …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026